Compare Twist Bioscience Corp (TWST) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Workiva Inc — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Workiva Inc trades at $72.76 (market cap $4.01B). The key difference: Twist Bioscience Corp is far larger — about 2.1× Workiva Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| TWST | WK | |
|---|---|---|
Market Cap | $8.42B | $4.01B |
Sector | Health | Technology |
52-Week High | $153.10 | $93.31 |
52-Week Low | $24.16 | $44.31 |
Enterprise Value | $8.35B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Workiva (WK) trades at $73.71, down 3.71% today, showing technical support near $72 with bullish moving averages. The company demonstrates strong revenue growth, with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and high analyst buy ratings (89%) support optimism, though elevated valuation ratios (P/E 87.75) warrant caution.
Outlook remains positive with consistent earnings beats and AI product launches driving growth. Key risks include high valuation multiples and competitive pressures in the SaaS sector. The consensus price target of $82.50 suggests 12% upside potential from current levels, supported by institutional accumulation and strong operational cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
